Replies to post #143431 on Biotech Values

[DewDiligence]

What happens to the FoB pathway if US Supreme Court invalidates ObamaCare?

Craig Wheeler (MNTA’s CEO) addressed this question on today’s GS webcast. Wheeler is extremely confident that, if ObamaCare is struck down, legislation restoring the 351(k) approval pathway for FoB’s will be quickly reinstated, possibly as an amendment to the PDUFA-renewal bill.

[DewDiligence]

Major FoB Collaborations

[TEVA and Samsung-BIIB have dropped Rituxan.]

 
                 Date   Targets  iHub References 
 Merck KGaA-RDY  6/12   oncology #msg-76359649 
 Daiichi-Coherus 5/12   *        #msg-75397629 
 Fujifilm-Kyowa  3/12   Humira   #msg-73800486 
 WPI-Bioton      2/12   insulin  #msg-74987123 
 WPI-AMGN       12/11   oncology #msg-70097496, #msg-70101928 
 BAX-MNTA       12/11   various  #msg-70212854, #msg-70258421 
 Samsung-BIIB   12/11   various  #msg-69629103, #msg-80622249 
 MRK-Hanwha      6/11   Enbrel   #msg-64164954, #msg-64193403  
 MYL-Biocon      6/09   various  #msg-39119393, #msg-72421544  
 TEVA-Lonza      1/09   various  #msg-34930012, #msg-80236315 
  
 *Enbrel and Rituxan in selected Asian countries.